Ovarian Cancer

Collaboration among surgical specialties allows for safe removal of all visible tumors, thus improving survival in patients with advanced ovarian cancer, says Donal J. Brennan, MB, PhD.

Mirvetuximab soravtansine-gynx may have the potential to become a new standard for patients with folate receptor α–positive, platinum-resistant ovarian cancer, experts say.

Data from the phase 3 MIRASOL trial support the European marketing authorization application for mirvetuximab soravtansine as a treatment for folate receptor α–positive, platinum-resistant ovarian cancer.

Patients with recurrent ovarian cancer did not see an improvement in efficacy when given atezolizumab plus chemotherapy and niraparib.

Results from the phase 3 FLAMES trial show an improved progression-free survival benefit with senaparib monotherapy vs placebo across all pre-specified patient subgroups with newly diagnosed, advanced ovarian cancer.

Investigators of a phase 2 study suggest that relacorilant may add to a ‘sparse’ field of effective treatment options for patients with platinum-resistant or refractory ovarian cancer.

Investigators are assessing AVB-001 as a treatment for those with high-grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube in a phase 1/2 trial.

IDE161 is now eligible for inclusion in a development program allowing for expediated regulatory review following its FDA fast track designation status for advanced BRCA1/2-mutant ovarian cancer.

A planned phase 1 trial will examine CDK12/13 inhibitor CT7439 in patients with several types of solid tumors, including breast and ovarian cancer, as well as Ewing’s sarcoma.

Patients with low-grade serous ovarian cancer appear to have worse survival outcomes following treatment with neoadjuvant chemotherapy.

Findings from an exploratory subgroup analysis in the phase 3 INNOVATE-3 trial suggest that Tumor Treating Fields plus paclitaxel may confer a survival benefit in patients who received only 1 prior line of therapy for platinum-resistant ovarian cancer.

Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.

The safety profile of upifitamab rilsodotin in the phase 1b/2 UPLIFT trial is consistent with prior reports of the agent in those with platinum-resistant ovarian cancer.

Treatment with batiraxcept plus paclitaxel did not produce any new safety signals among patients with platinum-resistant ovarian cancer in the phase 3 AXLerate-OC trial.

Data from the phase 3 PRIME trial show improved survival outcomes with frontline niraparib maintenance therapy among patients with advanced ovarian cancer.

Treatment with mirvetuximab soravtansine appears to produce a 3-fold improvement in objective response rate vs chemotherapy among patients with folate receptor-α–expressing, platinum-resistant ovarian cancer in the phase 3 MIRASOL trial.

"We’ve learned from our colleagues in breast cancer that there are opportunities to leverage this hormonal axis with combinations [including] a CDK4/6 [inhibitor]."

Following safety reports of bleeding events after treatment with upifitamab rilsodotin among patients with platinum-sensitive ovarian cancer, the FDA places a partial clinical hold on enrollment for the UP-NEXT and UPGRADE-A trials.

Olvimulogene nanivacirepvec virotherapy plus chemotherapy with or without bevacizumab produces a manageable safety profile in platinum-resistant or platinum-refractory ovarian cancer in the phase 2 VIRO-15 trial.

The panel explains how low-grade serous ovarian cancer differs from high-grade, and if an immunotherapy approach is appropriate for treatment.

Robert Coleman, MD, FACOG, FACS, reviews data from a study investigating combination letrozole plus ribociclib in patients with low-grade serous ovarian cancer.

PRGN-3005 autologous UltraCAR-T cells appear well-tolerated and decreases tumor burden in a population of patients with advanced platinum-resistant ovarian cancer.

Avutometinib plus defactinib produces no new safety signals among those with low-grade serous ovarian cancer in the phase 2 RAMP 201 trial.

The antitumor activity of niraparib maintenance therapy in patients with advanced ovarian cancer remains unclear among those with measurable residual disease at baseline in the phase 3 PRIME study.

Maintenance with niraparib also produces benefits in chemotherapy-free interval and time to first and second therapy among those with BRCA wild-type recurrent ovarian cancer in the phase 3 NOVA study.

Patients with folate receptor alpha (FRα)–high, platinum-resistant ovarian cancer experienced progression-free survival benefit following treatment with mirvetuximab soravtansine-gynx.

Maintenance bevacizumab plus durvalumab and olaparib appears to produce a progression-free survival benefit among those with HRD-negative advanced ovarian cancer in the phase 3 DUO-O trial.

Drs Eskander and Lewin discuss the sequencing immune checkpoint inhibitors for women with recurrent endometrial cancer.

Sharyn Lewin, MD, FACS, shares how she discusses side effects with patients receiving immune checkpoint inhibitors for advanced/recurrent endometrial cancer.

Experts explain what they are looking forward to in the future of treatment for patients with ER/PR+ and P53 wild-type or mutated advanced/recurrent endometrial cancer.